IFIzabel Feltrin Fabro

Izabel Feltrin Fabro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Izabel Feltrin Fabro has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The Ergogenic Effect of Caffeine in Rodents: A Systematic Review and Meta-Analysis, with a Narrative Synthesis of Adenosine A2A Receptor Mechanisms

    by Naiara de Souza Santos, Izabel Feltrin Fabro, Beatriz Carminati dos Santos, DébOra Maria Russiano Pereira, Aderbal Silva Aguiar

    Caffeine is a widely consumed ergogenic aid and a nonselective antagonist of adenosine receptors, including the facilitatory A2A subtype (A2AR), yet the magnitude of its performance-enhancing effect in rodents has not been formally quantified. We conducted a systematic review and meta-analysis of rodent studies administering caffeine before exercise, with risk of bias assessed using the SYRCLE tool (PROSPERO CRD420250653223). Fourteen studies met the eligibility criteria. Six studies of a single systemic dose preceding an aerobic task, comprising 71 animals were pooled using a restricted maximum likelihood random-effects model with a Hartung–Knapp interval, yielding a large ergogenic estimate with wide uncertainty (Hedges’ g = +1.31; 95% CI + 0.29 to +2.32; I2 = 71%). Prespecified rules, applied independently of the observed effects, precluded pooling of the two anaerobic studies, which measured different performance constructs, and of the three chronic-exposure studies, whose dosing regimens and exercise modalities were not comparable; these are reported descriptively, as are the intracerebral administration experiments. Risk of bias was frequently unclear or high in the randomization and blinding domains. Receptor-level evidence is reported separately as a narrative synthesis, because the search was not constructed to retrieve mechanistic studies: the ergogenic response was abolished in global and forebrain A2AR-knockout mice and reproduced by the selective antagonist SCH 58261, whereas A2AR agonism with NECA was ergolytic and reversed by caffeine, and deletion of CD73, which depletes the extracellular adenosine pool preferentially supplying A2AR, recapitulated the ergogenic phenotype. The rodent evidence provides preclinical support for A2AR involvement in exercise-induced fatigue on an evidence base too small and too heterogeneous to support therapeutic or performance translation.

  • Open Access

    Cannabigerol Enhances Muscle Strength and Performance in Dexamethasone-Treated Mice

    by Izabel Feltrin Fabro, Tatyana Nery, Ana Paula Pinto de AraújO, Amanda Leite Bastos Pereira, Francielly Andressa Felipetti, Aderbal Silva Aguiar Jr

    Sarcopenia is a major clinical condition associated with aging and is characterized by progressive loss of skeletal muscle mass and function. Resistance training is an effective intervention to counteract muscle atrophy; however, strategies that selectively enhance functional performance remain limited. Cannabigerol, a phytocannabinoid that is not a CB1 receptor agonist and therefore lacks psychotomimetic activity, has emerged as a potential modulator of neuromuscular function, although its role in skeletal muscle adaptation remains poorly understood. Here, we investigated the effects of resistance exercise and cannabigerol, alone and in combination, in a dexamethasone-induced model of muscle atrophy in mice. Animals received dexamethasone (20 mg/kg, i.p.) for 12 days and were subsequently subjected to a 4-week ladder-based resistance exercise protocol. Cannabigerol (10 mg/kg, i.p.) was administered on training days. Resistance exercise restored muscle morphology and improved fatigue resistance. In contrast, cannabigerol acted mainly on neuromuscular performance, increasing muscle power while producing only a small increase in fiber cross-sectional area. Cannabigerol potentiated training-induced power output, increasing performance by ∼55% in the first week and up to ∼87% after 4 weeks compared to exercise alone. In addition, cannabigerol increased peak grip strength (∼10%) and lowered post-exercise blood lactate in sedentary animals (∼48%). These findings show that resistance exercise and cannabigerol exert complementary effects on skeletal muscle─exercise promoting structural recovery and cannabigerol enhancing neuromuscular performance and lowering post-exercise lactate─and support further investigation of cannabigerol as an adjunct to exercise in glucocorticoid-induced muscle atrophy.

  • Open Access

    Central Blockade of Cannabinoid CB1 and CB2 Receptors Increases Force Generation in Reserpine-Treated Mice, but Only CB1 Blockade Extends the Duration of Effort

    by Beatriz Carminati dos Santos, Izabely Guedes da Rosa, LaízE de Freitas Mazzardo, Naiara de Souza Santos, Izabel Feltrin Fabro, Tatyana Nery, Amanda Leite Bastos Pereira, Aderbal S. Aguiar Jr

    Motor impairment in parkinsonism extends beyond the classical triad to weakness and a reduced capacity to sustain motor output, whose neuromodulatory control is poorly resolved. The endocannabinoid system is a candidate regulator, but CB1 and CB2 receptors have not been separated within one preparation. Reserpine-treated adult female Swiss mice received vehicle, the CB1 antagonist AM251, or the CB2 antagonist AM630 into the lateral ventricle; catalepsy was recorded across three trials and neuromuscular performance in a grip force task. Both antagonists increased the force generated at task onset, by amounts these data cannot distinguish: AM630 by 53.9 gf (95% CI 22.5–85.3) and AM251 by 41.2 gf (95% CI 8.8–73.6). They separated on duration. AM251 increased grip time by 619 ms (95% CI 113–1125), whereas AM630 did not (−70 ms, 95% CI −560 to +421). An interaction contrast on the force–time balance followed from that difference: AM630 shifted the balance toward force (−2.03 SD, P = 0.008), AM251 did not (−0.36 SD, P = 0.66), and the two differed from each other by 1.67 SD (P = 0.022). AM251 also reduced the odds of a cataleptic response (OR 0.16, 95% CI 0.03–0.89). Adjusting for body mass left both force effects unchanged. The dissociation is therefore in the duration of effort rather than in its force: both antagonists raise force, and only CB1 blockade also extends the time over which it is maintained. Delivered intracerebroventricularly, these effects are central in origin but not anatomically localized.

  • Open Access

    Purinergic P2X7 Receptor Antagonism Impairs Aerobic Capacity without Detectable Effect on Cardiac Adaptation to Exercise in Mice

    by Naiara de Souza Santos, Izabel Feltrin Fabro, Ana Paula Pinto de AraújO, Beatriz Carminati dos Santos, Tatyana Nery, SávIo de Almeida Ramos, Izabely Guedes da Rosa, Francielly Andressa Felipetti, Amanda Leite Bastos-Pereira, Aderbal S. Aguiar

    Adenosine triphosphate (ATP) signaling through the P2X7 receptor is an emerging determinant of mitochondrial energy metabolism and physical fitness, and the receptor is increasingly targeted pharmacologically for its role in inflammation. Whether systemic P2X7 antagonism affects aerobic capacity and the structural adaptation of the heart to exercise is unknown. Adult male Swiss mice were studied in a 2 × 2 factorial design crossing physical conditioning (sedentary or exercised) with treatment (saline or the P2X7 antagonist Brilliant Blue G, BBG; 50 mg/kg). Exercised animals trained on a treadmill on alternate days over approximately 4 weeks; maximal oxygen uptake (V̇O2max) and power were measured by incremental treadmill ergospirometry, and myocardial cardiomyocyte volume density (Vv) was quantified by design-based stereology. Aerobic training increased V̇O2max and cardiomyocyte Vv. BBG reduced V̇O2max and peak power independently of training and produced a deficit that widened progressively with workload across the incremental test, indicating a demand-dependent limitation of oxidative performance. Critically, BBG did not detectably alter the exercise-induced increase in cardiomyocyte Vv and showed no interaction with training; motor coordination, locomotor and exploratory behavior, blood lactate, and body mass were also unaffected. P2X7 antagonism thus impairs aerobic capacity without detectable blunting of the structural response of the heart to exercise. This functional–structural dissociation points to a metabolic process, plausibly mitochondrial, rather than to cardiac remodeling, although the present sample size bounds rather than excludes an effect on cardiac adaptation, and indicates that P2X7-directed therapies may reduce exercise capacity without producing overt cardiac structural change.

  • Impact of CB1 receptor antagonism on skeletal muscle hypertrophy and metabolic health: a systematic review of preclinical studies

    by Newton Kleber de Abreu Júnior, Izabel Fabro Feltrin, Débora Maria Russiano Pereira, Poliana Penasso Bezerra, Aderbal S. Aguiar

    The endocannabinoid system (ECS), regulating such processes as energy homeostasis, inflammation, and muscle function, centers around cannabinoid receptors, including CB1. These receptors are mainly located in the central nervous system and skeletal muscles. Hyperactivity of CB1 receptors is linked to metabolic disorders and chronic inflammation, highlighting their potential as therapeutic targets for muscle hypertrophy and metabolic health. This systematic review, registered with PROSPERO (CRD42023462735), follows PRISMA-P guidelines and uses the PICO framework. It evaluates the effects of CB1 receptor antagonism on muscle hypertrophy in animal models and cell lines. Interventions include pharmacological antagonists, genetic modifications, and exercise-induced antagonism. A comprehensive search of databases such as PubMed, EMBASE, CINAHL, and SPORTDiscus, supplemented by gray literature and reference lists, yielded 571 references. From these, ten studies were selected, involving 338 rodents, using CB1 antagonists like rimonabant and AM251. The findings suggest that CB1 receptor antagonism enhances insulin sensitivity and glucose tolerance, reduces body fat, and promotes muscle growth through pathways such as PI3K/Akt and mTOR, as well as by improving autophagy and mitochondrial function. This review proposes CB1 receptor antagonism as a promising approach for enhancing muscle hypertrophy and improving metabolic health, with potential applications in treating such conditions as obesity, type 2 diabetes, and sarcopenia. Future research should aim to standardize intervention protocols and explore integrated therapies to fully harness the benefits of CB1 modulation.